NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: HeartBeam Inc.'s FDA-Cleared 3D ECG Technology and Industry Recognition
TL;DR
HeartBeam's FDA-cleared 12-lead ECG software offers investors and competitors an edge in remote cardiac monitoring with strong IP ranking second globally.
HeartBeam's portable device captures 3D heart signals and synthesizes them into standard 12-lead ECGs using 82 patents across 15 families for remote clinical review.
HeartBeam's technology enables earlier cardiac condition detection outside medical facilities, improving access to care and potentially saving lives through remote monitoring.
HeartBeam ranks second worldwide in portable cardiac diagnostics innovation, trailing only GE Healthcare among 243 companies evaluated for 12-lead ECG technology.
Found this article helpful?
Share it with your network and spread the knowledge!
The content covers HeartBeam Inc.'s FDA clearance for its 12-lead electrocardiogram synthesis software and its recognition as a global IP and technology leader in portable cardiac diagnostics.
HeartBeam's 12-lead electrocardiogram synthesis software was cleared by the FDA on December 8 to assess arrhythmias by converting 3D heart signal data into a standard 12-lead ECG format suitable for remote clinical review.
The technology uses a portable, non-invasive recorder to capture heart signal data from three dimensions, then converts this data into a standard 12-lead ECG format through synthesis software for remote clinical review.
HeartBeam was recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide in 12-lead ECG innovation among 243 companies evaluated in PatentVest's 'Total Cardiac Intelligence' report.
HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG, designed for portable use outside medical facilities.
HeartBeam has 82 global patent publications across 15 patent families supporting its three-dimensional cardiac signal capture and 12-lead ECG synthesis architecture, reflecting a strong IP foundation for its remote cardiac monitoring technology.
HeartBeam was highlighted in a January 8 report by Modern Healthcare that outlined FDA clearances and approvals across the medical device sector.
You can visit https://ibn.fm/pfPB1 to learn more about HeartBeam's Portable ECG Technology.
For additional information, visit HeartBeam.com or the company's newsroom at https://ibn.fm/BEAT.
The technology enables physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining the future of remote cardiac health management.
Curated from InvestorBrandNetwork (IBN)
